Published in Nucleic Acids Res on February 18, 2005
Audioprofile-directed screening identifies novel mutations in KCNQ4 causing hearing loss at the DFNA2 locus. Genet Med (2008) 1.49
Development of a high-throughput resequencing array for the detection of pathogenic mutations in osteogenesis imperfecta. PLoS One (2015) 1.46
Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A (2006) 1.35
Multi-stringency wash of partially hybridized 60-mer probes reveals that the stringency along the probe decreases with distance from the microarray surface. Nucleic Acids Res (2008) 1.05
Mutation screening of multiple genes in Spanish patients with autosomal recessive retinitis pigmentosa by targeted resequencing. PLoS One (2011) 1.01
Identification of novel mutations and sequence variation in the Zellweger syndrome spectrum of peroxisome biogenesis disorders. Hum Mutat (2009) 0.99
High throughput genetic analysis of congenital myasthenic syndromes using resequencing microarrays. PLoS One (2007) 0.84
Development of a physical model-based algorithm for the detection of single-nucleotide substitutions by using tiling microarrays. PLoS One (2013) 0.81
Insights into N-calls of mitochondrial DNA sequencing using MitoChip v2.0. BMC Res Notes (2011) 0.77
Microarray-based DNA resequencing using 3' blocked primers. Anal Biochem (2007) 0.76
Influence of the length of target DNA overhang proximal to the array surface on discrimination of single-base mismatches on a 25-mer oligonucleotide array. BMC Res Notes (2014) 0.75
Insight into the sequence specificity of a probe on an Affymetrix GeneChip by titration experiments using only one oligonucleotide. Biophysics (Nagoya-shi) (2007) 0.75
Specific mutation screening of TP53 gene by low-density DNA microarray. Nanotechnol Sci Appl (2009) 0.75
Exclusion/confirmation of ataxia-telangiectasia via cell-cycle testing. Eur J Pediatr (2006) 0.75
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol (1999) 41.48
Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet (1999) 24.24
Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science (1998) 18.23
ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer (2003) 16.06
Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science (2001) 15.54
Light-directed, spatially addressable parallel chemical synthesis. Science (1991) 15.09
Accessing genetic information with high-density DNA arrays. Science (1996) 13.89
A model of molecular interactions on short oligonucleotide microarrays. Nat Biotechnol (2003) 9.98
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
High-throughput variation detection and genotyping using microarrays. Genome Res (2001) 5.24
Prediction of hybridization and melting for double-stranded nucleic acids. Biophys J (2004) 5.11
Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse. Nat Genet (2000) 4.66
OligoArray 2.0: design of oligonucleotide probes for DNA microarrays using a thermodynamic approach. Nucleic Acids Res (2003) 4.64
Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nat Genet (1996) 4.19
Resequencing and mutational analysis using oligonucleotide microarrays. Nat Genet (1999) 3.95
Probe selection for high-density oligonucleotide arrays. Proc Natl Acad Sci U S A (2003) 3.31
DNA analysis and diagnostics on oligonucleotide microchips. Proc Natl Acad Sci U S A (1996) 3.13
Evolutionarily conserved sequences on human chromosome 21. Genome Res (2001) 2.95
Modeling of DNA microarray data by using physical properties of hybridization. Proc Natl Acad Sci U S A (2003) 2.95
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. Genome Res (2004) 2.47
Strategies for mutational analysis of the large multiexon ATM gene using high-density oligonucleotide arrays. Genome Res (1998) 2.17
Sequence specific thermodynamic and structural properties for DNA.RNA duplexes. Biochemistry (1994) 2.16
Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A (1999) 2.08
Mutational analysis using oligonucleotide microarrays. J Med Genet (1999) 2.05
Segmental phylogenetic relationships of inbred mouse strains revealed by fine-scale analysis of sequence variation across 4.6 mb of mouse genome. Genome Res (2004) 1.93
Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem (2000) 1.85
Flexible use of high-density oligonucleotide arrays for single-nucleotide polymorphism discovery and validation. Genome Res (2001) 1.55
Prioritized selection of oligodeoxyribonucleotide probes for efficient hybridization to RNA transcripts. Nucleic Acids Res (2003) 1.52
Thermodynamic calculations and statistical correlations for oligo-probes design. Nucleic Acids Res (2003) 1.49
Genomic DNA insertions and deletions occur frequently between humans and nonhuman primates. Genome Res (2003) 1.38
Solution structures of DNA.RNA hybrids with purine-rich and pyrimidine-rich strands: comparison with the homologous DNA and RNA duplexes. Biochemistry (1998) 1.37
Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays. Hum Mutat (1996) 1.36
Thermodynamic parameters for an expanded nearest-neighbor model for the formation of RNA duplexes with single nucleotide bulges. Biochemistry (2002) 1.34
The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer. Nat Genet (2004) 1.25
Sequence variation in genes and genomic DNA: methods for large-scale analysis. Annu Rev Genomics Hum Genet (2000) 1.24
New developments in high-throughput resequencing and variation detection using high density microarrays. Hum Mutat (2002) 1.19
Enhanced high density oligonucleotide array-based sequence analysis using modified nucleoside triphosphates. Nucleic Acids Res (1998) 1.11
High-density genechip oligonucleotide probe arrays. Adv Biochem Eng Biotechnol (2002) 1.10
Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci U S A (2003) 1.08
Oligonucleotide microarray based detection of repetitive sequence changes. Hum Mutat (2000) 1.06
Two color hybridization analysis using high density oligonucleotide arrays and energy transfer dyes. Nucleic Acids Res (1998) 1.05
Sequence-independent and linear variation of oligonucleotide DNA binding stabilities. Nucleic Acids Res (1996) 1.05
ATM gene and lymphoid malignancies. Leukemia (2004) 1.04
Improving the sensitivity and specificity of gene expression analysis in highly related organisms through the use of electronic masks. Nucleic Acids Res (2004) 1.03
Structural features and stability of an RNA triple helix in solution. Nucleic Acids Res (1996) 1.01
The effect of base sequence on the stability of RNA and DNA single base bulges. Biochemistry (1999) 0.96
Clinical application of oligonucleotide probe array for full-length gene sequencing of TP53 in colon cancer. Oncology (2003) 0.85
Analysis of SNPs and other genomic variations using gel-based chips. Hum Mutat (2002) 0.82
High-density nucleoside analog probe arrays for enhanced hybridization. Nucleosides Nucleotides (1999) 0.78
Identification of TP53 mutations in human cancers using oligonucleotide microarrays. Methods Mol Med (2004) 0.78
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol (2008) 3.71
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol (2007) 2.83
Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res (2008) 2.81
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
The origin of malignant malaria. Proc Natl Acad Sci U S A (2009) 2.67
Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol (2006) 2.55
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol (2006) 2.01
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol (2004) 2.00
GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res (2006) 1.96
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol (2006) 1.92
Comparative analysis of gene-expression patterns in human and African great ape cultured fibroblasts. Genome Res (2003) 1.92
A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics (2004) 1.88
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.85
Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol (2009) 1.79
Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol (2007) 1.74
Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol (2007) 1.74
Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst (2002) 1.72
Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res (2004) 1.71
Molecular determinants of cetuximab efficacy. J Clin Oncol (2005) 1.56
Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer (2013) 1.51
Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol (2005) 1.45
Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med (2004) 1.43
A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res (2011) 1.40
Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol (2003) 1.39
Modulation of noncanonical TGF-β signaling prevents cleft palate in Tgfbr2 mutant mice. J Clin Invest (2012) 1.37
Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A (2006) 1.35
Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol (2009) 1.32
ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol (2003) 1.27
Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials. Clin Trials (2013) 1.27
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol (2006) 1.25
Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol (2011) 1.25
Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res (2005) 1.25
Identification of novel candidate genes involved in mineralization of dental enamel by genome-wide transcript profiling. J Cell Physiol (2012) 1.24
Temozolomide for treatment-resistant recurrent meningioma. Neurology (2004) 1.23
Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res (2005) 1.20
Gene expression profiling of glucocorticoid-inhibited osteoblasts. J Mol Endocrinol (2004) 1.20
Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone. Prostate (2008) 1.19
LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics (2009) 1.17
Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol (2006) 1.16
Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids (2002) 1.15
Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics (2006) 1.14
Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol (2005) 1.13
Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol (2005) 1.13
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics (2009) 1.12
Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res (2005) 1.11
DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer (2007) 1.11
Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol (2009) 1.11
Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. BJU Int (2011) 1.10
Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res (2003) 1.10
Fibroblast growth factor 9 (FGF9)-pituitary homeobox 2 (PITX2) pathway mediates transforming growth factor β (TGFβ) signaling to regulate cell proliferation in palatal mesenchyme during mouse palatogenesis. J Biol Chem (2011) 1.10
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics (2006) 1.09
Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer (2005) 1.09
Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci U S A (2003) 1.08
Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol (2006) 1.08
Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol (2003) 1.07
Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem (2002) 1.05
Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. J Histochem Cytochem (2003) 1.05
Water intake and bladder cancer risk in Los Angeles County. Int J Cancer (2008) 1.05
RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res (2008) 1.05
Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol (2004) 1.03
Improving the sensitivity and specificity of gene expression analysis in highly related organisms through the use of electronic masks. Nucleic Acids Res (2004) 1.03
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol (2009) 1.03
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer (2013) 1.03
GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer (2011) 1.01
[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med (2008) 1.01
Synthesis and anticancer properties of water-soluble zinc ionophores. Cancer Res (2008) 1.01
Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg (2005) 1.00
Gene-expression analysis of early- and late-maturation-stage rat enamel organ. Eur J Oral Sci (2011) 1.00
Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol (2009) 1.00
Identification of novel mutations and sequence variation in the Zellweger syndrome spectrum of peroxisome biogenesis disorders. Hum Mutat (2009) 0.99
Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics (2008) 0.98
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res (2012) 0.97
Emergence of a novel and highly divergent HTLV-3 in a primate hunter in Cameroon. Virology (2010) 0.97
Overexpression of E-cadherin protein in metastatic breast cancer cells in bone. Anticancer Res (2008) 0.96
Identification of micrometastases in histologically negative lymph nodes of early-stage cervical cancer patients. Obstet Gynecol (2004) 0.96
Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res (2005) 0.96
Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J Neuroimmunol (2004) 0.96
Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis (2002) 0.95
The circadian clock modulates enamel development. J Biol Rhythms (2012) 0.94
Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations. J Cell Biochem (2011) 0.94
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol (2012) 0.94
Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. Mol Cancer Res (2007) 0.92
HIV type 1 pol gene diversity and genotypic antiretroviral drug resistance mutations in Malabo, Equatorial Guinea. AIDS Res Hum Retroviruses (2010) 0.92
A TGFβ-Smad4-Fgf6 signaling cascade controls myogenic differentiation and myoblast fusion during tongue development. Development (2012) 0.92
mtDNA depletion confers specific gene expression profiles in human cells grown in culture and in xenograft. BMC Genomics (2008) 0.91
Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol (2011) 0.91
Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer (2003) 0.91
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol (2015) 0.91
Leaky ribosomal scanning in mammalian genomes: significance of histone H4 alternative translation in vivo. Nucleic Acids Res (2005) 0.90
The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate (2010) 0.89
Identification of differences in human and great ape phytanic acid metabolism that could influence gene expression profiles and physiological functions. BMC Physiol (2010) 0.89